글로벌 급성 소엽성 신염 치료 시장 – 2031년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

글로벌 급성 소엽성 신염 치료 시장 – 2031년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Upcoming Report
  • Apr 2024
  • Global
  • 350 Pages
  • 테이블 수: 220
  • 그림 수: 60

Global Acute Lobar Nephronia Treatment Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2024 –2031
Diagram 시장 규모(기준 연도)
USD 9.21 Billion
Diagram 시장 규모(예측 연도)
USD 12.13 Billion
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>글로벌 급성 소엽성 신염 치료 시장, 유형별(단일엽 감염 및 다발엽 감염), 약물(항생제, 항염제, 진통제), 약물 유형(브랜드 및 제네릭), 투여 경로(경구 및 비경구), 인구 유형(어린이 및 성인), 최종 사용자(병원, 전문 클리닉 및 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국 및 기타) - 업계 동향 및 2031년까지의 예측.

급성 소엽성 신염 치료 시장

급성 소엽성 신염 치료 시장 분석 및 규모

연구 기관은 질환에 대한 이해를 개선하고, 혁신적인 치료법을 개발하고, 기존 치료법의 효능을 평가하기 위한 연구를 수행하여 급성 소엽성 신염 치료 시장을 발전시키는 데 중요한 역할을 합니다. 그들은 새로운 진단 기술, 항생제 및 치료 프로토콜을 탐구하여 환자 결과를 개선하고 세균성 신장 감염의 부담을 줄입니다. 이러한 기여는 이 질환을 둘러싼 지식 기반을 확장하고 임상 실무의 진전을 촉진하여 궁극적으로 전 세계 환자에게 이롭습니다.

글로벌 급성 소엽성 신염 치료 시장 규모는 2023년에 92억 1,000만 달러로 평가되었으며, 2031년까지 1,213억 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 3.50%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

보고서 메트릭

세부

예측 기간

2024-2031

기준 연도

2023

역사적 연도

2022 (2016-2021년까지 사용자 정의 가능)

양적 단위

매출은 10억 달러, 볼륨은 단위, 가격은 10억 달러

다루는 세그먼트

유형(단일엽 감염 및 다발엽 감염), 약물(항생제, 항염제, 진통제), 약물 유형(브랜드 및 제네릭), 투여 경로(경구 및 비경구), 인구 유형(어린이 및 성인), 최종 사용자(병원, 전문 클리닉 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국 및 기타)

적용 국가

미국, 캐나다 및 멕시코(북미), 독일, 프랑스, ​​영국, 네덜란드, 스위스, 벨기에, 러시아, 이탈리아, 스페인, 터키, 유럽의 기타 유럽, 중국, 일본, 인도, 한국, 싱가포르, 말레이시아, 호주, 태국, 인도네시아, 필리핀, 아시아 태평양(APAC)의 기타 아시아 태평양(APAC), 사우디 아라비아, UAE, 남아프리카, 이집트, 이스라엘, 중동 및 아프리카(MEA)의 일부인 기타 중동 및 아프리카(MEA), 브라질, 아르헨티나 및 남미의 일부인 기타 남미

시장 참여자 포함

Hikma Pharmaceuticals PLC (U.K.), Pfizer Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Antares Pharma (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi USA (U.S.), Accord Healthcare, Inc. (U.S.), GSK plc (U.K.), Lilly (U.S.), Abbott (U.S.), Sanofi (France), Bayer AG (Germany), Amgen Inc. (U.S.)

Market Opportunities

  • Growing Advancements in Medical Technology Promotes Precise Treatment of Acute Lobar Nephronia
  • Rise in Adoption of Acute Lobar Nephronia Treatments due to the Growing Aging Population

Market Definition

Acute lobar nephronia treatment typically involves aggressive antibiotic therapy to target the bacterial infection in the affected kidney lobe. Intravenous antibiotics are often administered initially, followed by oral antibiotics for continued treatment. In severe cases, hospitalization may be required for close monitoring and intravenous antibiotic administration.

Acute Lobar Nephronia Treatment Market Dynamics

Drivers

  • Growing Demand for Effective Treatments due to Increasing Incidence of Acute Lobar Nephronia

As bacterial kidney infections become more prevalent, there is a heightened need for swift and efficient therapeutic interventions to address this condition. This growing demand stems from the potentially severe consequences of untreated ALN, such as renal scarring and kidney damage, underscoring the urgency for effective treatment options. It fosters the development of novel medications and encourages the adoption of advanced diagnostic techniques, ultimately enhancing patient outcomes and driving market growth.

For instance, In October 2023, amidst Alnylam Pharmaceuticals' commitment to innovation, positive interim results were reported for ALN-APP, an investigational RNAi therapeutic targeting Alzheimer's disease. These promising findings align with the growing demand for effective treatments in the acute lobar nephronia treatment market, reflecting the pharmaceutical industry's dedication to addressing complex medical conditions through advanced therapies.

  • Surge in Research and Development Initiatives Increases the Demand for Acute Lobar Nephronia Treatment

Increased investment in R&D by pharmaceutical companies and academic institutions fuels the discovery of novel antibiotics, diagnostic tools, and treatment modalities tailored for acute lobar nephronia. It enhance the efficacy of existing treatments and lead to the development of more targeted and efficient therapies. Furthermore, R&D efforts contribute to a deeper understanding of the underlying mechanisms of the condition, enabling the development of personalized treatment approaches. Ultimately, the continuous innovation driven by R&D initiatives promises improved patient outcomes and drives the growth of the acute lobar nephronia treatment market.

Opportunities

  • Growing Advancements in Medical Technology Promotes Precise Treatment of Acute Lobar Nephronia

Sophisticated diagnostic tools such as CT scans, MRI, and ultrasound allow healthcare professionals to identify acute lobar nephronia at its onset, facilitating timely intervention. Technological innovations in antibiotic therapy delivery systems ensure targeted and efficient administration of medications, optimizing treatment outcomes while minimizing adverse effects. The continuous evolution of medical technology empowers healthcare providers to offer personalized and effective care to patients with acute lobar nephronia, thereby driving market growth and improving patient prognosis.

For instance, in 2024, Medtronic's advancements in healthcare technology, particularly AI integration, are transforming patient care. The latest GI Genius endoscopy system enhances polyp detection, potentially aiding early diagnosis of conditions such as acute lobar nephronia, while strategic collaborations with Modernizing Medicine promise streamlined workflows and improved efficiency in healthcare delivery.

  • Rise in Adoption of Acute Lobar Nephronia Treatments due to the Growing Aging Population

As people age, there is a natural decline in kidney function and immunity, making the elderly more susceptible to bacterial infections such as acute lobar nephronia. Moreover, age-related comorbidities, such as diabetes and hypertension, further increase the risk of developing kidney infections. The demographic shift towards an older population demographic globally amplifies the prevalence of acute lobar nephronia cases. Consequently, healthcare systems are compelled to allocate resources towards diagnosing and treating these infections in the elderly, driving demand for acute lobar nephronia treatments and contributing to market growth.

Restraints/Challenges

  • Risk of Antibiotic Resistance limits the Adoption of Acute Lobar Nephronia Treatment

Prolonged or inappropriate use of antibiotics can lead to the development of resistant strains of bacteria, rendering traditional antibiotic therapies ineffective. This poses a serious challenge for treating acute lobar nephronia, as antibiotic resistance limits the available treatment options and increases the such aslihood of treatment failure and disease recurrence. Antibiotic resistance raises concerns about patient safety and outcomes, as infections become more difficult to manage and control, leading to poorer prognoses and increased healthcare costs.

  • High Treatment Costs Impacting Healthcare Systems

The expenses associated with hospitalization, diagnostic tests, antibiotic therapies, and follow-up care can strain healthcare budgets, leading to financial challenges for both patients and providers. This can result in delayed or inadequate treatment, ultimately affecting patient outcomes. The economic burden of treating acute lobar nephronia may divert resources away from other essential healthcare services, exacerbating disparities in access to care.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Acute Lobar Nephronia Treatment Market Scope

The market is segmented on the basis of type, drug, drug type, route of administration, population type, distribution channel and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Single Lobe Infection
  • Multiple Lobe Infection

Drug

Drug Type

  • Branded
  • Generics

Route of Administration

  • Oral
  • Parenteral

Population Type

  • Children
  • Adults

End Users

  • Hospitals
  • Specialty Clinic
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

Acute Lobar Nephronia Treatment Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by type, drug, drug type, route of administration, population type, distribution channel and end users as referenced above.

The major countries covered in the market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to robust reimbursement policies in the U.S. and a surge in awareness and research efforts dedicated to addressing prevalent diseases. The U.S. healthcare system's comprehensive reimbursement policies incentivize innovation and treatment accessibility, fostering a conducive environment for market growth. Simultaneously, heightened awareness campaigns and increased research funding contribute to a deeper understanding and management of diseases, further propelling North America's market dominance in the forecasted period.

Asia-Pacific is experiencing a surge in research and development investments, particularly in the healthcare sector. This heightened focus on innovation is driving breakthroughs in medical technology and treatments, creating lucrative opportunities for investors and stakeholders. Additionally, governments and private entities in the region are increasing their healthcare expenditure, fostering a conducive environment for growth and advancement in healthcare services. As a result, the Asia-Pacific region is positioned as a key hub for lucrative opportunities in healthcare, attracting both domestic and international interest.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Acute Lobar Nephronia Treatment Market Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market

Key players operating in the market include:

  • Hikma Pharmaceuticals PLC (U.K.)
  • Pfizer Inc. (U.S.)
  • 브리스톨-마이어스 스퀴브 회사(미국)
  • 안타레스파마(미국)
  • 노바티스 AG(스위스)
  • Teva Pharmaceutical Industries Ltd(이스라엘)
  • F. 호프만-라 로슈 유한회사(스위스)
  • 프레제니우스 카비 USA (US)
  • Accord Healthcare, Inc. (미국)
  • GSK plc (영국)
  • 릴리(미국)
  • 애벗(미국)
  • 사노피(프랑스)
  • Bayer AG(독일)
  • 암젠 주식회사(미국)


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The acute lobar nephronia treatment market size will be worth USD 12.13 billion by 2031.
The growth rate of the acute lobar nephronia treatment market is 3.50%.
Growing Demand for Effective Treatments due to Increasing Incidence of Acute Lobar Nephronia & Surge in Research and Development Initiatives Increases the Demand for Acute Lobar Nephronia Treatment are the growth drivers of the acute lobar nephronia treatment market.
Type, drug, drug type, route of administration, population type, distribution channel and end users are the factors on which the acute lobar nephronia treatment market research is based.
Major companies in the acute lobar nephronia treatment market are Hikma Pharmaceuticals PLC (U.K.), Pfizer Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Antares Pharma (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi USA (U.S.), Accord Healthcare, Inc. (U.S.), GSK plc (U.K.), Lilly (U.S.), Abbott (U.S.), Sanofi (France), Bayer AG (Germany), Amgen Inc. (U.S.).